ADIPOQ and metabolic syndrome: It demonstrated a systemic effect of the drug with decreased weight gain, improved insulin sensitivity (HOMA-IR, adiponectin), dyslipidemia (triglycerides and cholesterol) along with resolution of steatohepatitis and improvement in all of the key histological features of NASH.